The pain game: With safety concerns slowing traditional treatments, new options are filling the void
April 16th 2007Debilitating pain-affecting millions of Americans-was often alleviated by traditional nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors. But the appeal of these once-popular drugs is declining due to safety concerns.
Valve risk leads to withdrawal of pergolide (Permax, Valiant)
April 16th 2007Two high-quality reports in the New England Journal of Medicine confirming the risk of valvulopathy with the use of pergolide (Permax, Valiant) have led the FDA to remove the drug from the U.S. market. Two generic forms of the drug, made by Teva and Par Pharmaceuticals, will also be withdrawn.
Tigan suppositories removed from market
April 16th 2007Trimethobenzamide-containing suppositories are the next product in line to hit the FDA's chopping block as part of the agency's ongoing effort to ensure that all marketed drugs have been officially approved. The rectally administered treatment of nausea and vomiting has been available under the brand names Tigan, Tebamide, Trimazide, Trimethobenz, and T-Gen.
CHPA campaign to help seniors manage drugs
April 16th 2007The Consumer Healthcare Products Association's (CHPA) educational foundation, the Consumer Health Education Center, has launched a national education campaign to help mature Americans better mange their health, specifically regarding the OTCs they use.
Latebreakers: CMS clarifies National Provider Identifier (NPI) rule as deadline looms
April 16th 2007Less than two months before a May 23 deadline, CMS has finally offered public recognition that many healthcare providers may not be ready for the changeover to the National Provider Identifier (NPI) standards.
Of two minds: New research finds atypicals are just a modest improvement in schizophrenia treatment
April 16th 2007Antipsychotic agents have long been integral to the management of schizophrenia. First-generation, "conventional" antipsychotics are high-affinity antagonists of dopamine D2 receptors. Although they are effective against antipsychotic symptoms, they are also associated with a high rate of neurologic adverse effects. Such effects include tardive dyskinesia and extrapyramidal symptoms (EPS).
The pain game: With safety concerns slowing traditional treatments, new options are filling the void
April 16th 2007Debilitating pain-affecting millions of Americans-was often alleviated by traditional nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors. But the appeal of these once-popular drugs is declining due to safety concerns.
Infection surveillance software can save lives
April 16th 2007As many as 100,000 patients die every year from hospital-acquired infections. It doesn't have to be that way. HAIs are eminently preventable. Tools exist that can significantly lower HAI mortality and morbidity rates and reduce an associated $6 billion in excess annual health costs.
Controversy continues to surround generic insulin
April 16th 2007Diabetes is a deadly, common and costly disease, so the debate about biogenerics is ardent when it concerns insulin. The drug is expensive and indispensable, and scientists agree that creating generic insulin is simpler than creating most other potential biologic equivalents.
Clinical twisters: Assessing risk to QT interval
April 16th 2007A 70-year-old woman, T.R., has been transferred from an extended care nursing facility to your hospital with symptoms of fever, dyspnea with respiratory difficulty, cough, and sputum production. Her current medications include methadone 200 mg/ day (pain syndrome), risperidone (Risperdal, Janssen) 2 mg twice daily, digoxin 0.125 mg daily, and furosemide 20 mg twice daily.